Portal de Periódicos da CAPES

The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis registry - a resource for clinical practice and research

2006; Wiley; Volume: 113; Issue: s183 Linguagem: Inglês

10.1111/j.1600-0404.2006.00613.x

1600-0404

Kjell‐Morten Myhr, Nina Grytten, J. H. Aarseth, Harald Nyland,

Viral Infections and Immunology Research

Acta Neurologica ScandinavicaVolume 113, Issue s183 p. 37-40 The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis registry – a resource for clinical practice and research K.-M. Myhr, K.-M. Myhr Multiple Sclerosis National Competence Centre Department of Clinical Medicine, Section for Neurology, University of Bergen, Bergen, NorwaySearch for more papers by this authorN. Grytten, N. Grytten Multiple Sclerosis National Competence CentreSearch for more papers by this author J. H. Aarseth, J. H. Aarseth National MS registry, Department of Neurology, Haukeland University HospitalSearch for more papers by this authorH. Nyland, H. Nyland Multiple Sclerosis National Competence Centre Department of Clinical Medicine, Section for Neurology, University of Bergen, Bergen, NorwaySearch for more papers by this author K.-M. Myhr, K.-M. Myhr Multiple Sclerosis National Competence Centre Department of Clinical Medicine, Section for Neurology, University of Bergen, Bergen, NorwaySearch for more papers by this authorN. Grytten, N. Grytten Multiple Sclerosis National Competence CentreSearch for more papers by this author J. H. Aarseth, J. H. Aarseth National MS registry, Department of Neurology, Haukeland University HospitalSearch for more papers by this authorH. Nyland, H. Nyland Multiple Sclerosis National Competence Centre Department of Clinical Medicine, Section for Neurology, University of Bergen, Bergen, NorwaySearch for more papers by this author First published: 24 March 2006 https://doi.org/10.1111/j.1600-0404.2006.00613.xCitations: 21 Kjell-Morten Myhr, Department of Neurology, Haukeland University Hospital, N-5021 Bergen, Norway Tel.: +47 55975045 Fax: +47 55975901 e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract The Norwegian Multiple Sclerosis National Competence Centre was established at the Department of Neurology, Haukeland University Hospital, Bergen in 1996. Promotion of research, supervision and education of doctors and other health care professionals in Norway are the main responsibilities of the Centre. The centre has established national networks for MS care and research and has provided supervision and education of doctors and other health care professionals in Norway. Guidelines for diagnosis and treatment of MS have been established. The National Multiple Sclerosis Registry was established in 1998 and includes by January 2006 50–60% of all MS patients in Norway. Through a national collaboration, the registry aims for inclusion of a biobank unit for collection of cerebrospinal fluid and serum, DNA, and tissue samples. References 1 Myhr KM. Epidemiological data on multiple sclerosis. Tidsskr Nor Laegeforen. 2005; 125: 414. 2 Swank RL, Lerstad O, Strom A, Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med 1952; 246: 722– 8. 3 Presthus J. Report on the multiple sclerosis investigations in West-Norway. Acta Psychiatr Scand 1960; 35: 88– 92. 4 Oftedal SI. Multiple sclerosis in Vestfold county. Acta Neurol Scand 1965; 16: 1– 62. 5 Frovig AG, Presthus J, Sponheim N. The significance of allergy in the etiology and pathogenesis of multiple sclerosis. Acta Neurol Scand 1967; 43: 215– 27. 6 Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand 1970; 46: 455– 83. 7 Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler 1999; 5: 293– 6. 8 Nyland H, Matre R. Fcgamma receptors in human choroid plexus. Acta Pathol Microbiol Scand 1978; 86: 141– 3. 9 Nyland H, Mork S, Matre R. In-situ characterisation of mononuclear cell infiltrates in lesions of multiple sclerosis. Neuropathol Appl Neurobiol 1982; 8: 403– 11. 10 Nyland H, Matre R, Mork S. Fc receptors of microglial lipophages in multiple sclerosis. N Engl J Med 1980; 302: 120– 1. 11 Vedeler C, Ulvestad E, Grundt I et al. Fc receptor for IgG (FcR) on rat microglia. J Neuroimmunol. 1994; 49: 19– 24. 12 Ulvestad E, Williams K, Matre R, Nyland H, Olivier A, Antel J. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets. J Neuropathol Exp Neurol 1994; 53: 27– 36. 13 Kruger PG, Bo L, Myhr KM et al. Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasising staining procedures. Acta Neurol Scand 1990; 81: 31– 6. 14 Larsen JP, Aarli JA, Nyland H, Riise T. Western Norway, a high-risk area for multiple sclerosis: a prevalence/incidence study in the county of Hordaland. Neurology 1984; 34: 1202– 7. 15 Riise T, Klauber MR. Relationship between the degree of individual space-time clustering and age at onset of disease among multiple sclerosis patients. Int J Epidemiol 1992; 21: 528– 32. 16 Gronning M, Riise T, Kvale G, Nyland H, Larsen JP, Aarli JA. Incidence of multiple sclerosis in Hordaland, western Norway: a fluctuating pattern. Neuroepidemiology 1991; 10: 53– 61. 17 Edland A, Nyland H, Riise T, Larsen JP. Epidemiology of multiple sclerosis in the county of Vestfold, eastern Norway: incidence and prevalence calculations. Acta Neurol Scand 1996; 93: 104– 9. 18 Midgard R, Riise T, Nyland H. Epidemiologic trends in multiple sclerosis in Møre and Romsdal, Norway: a prevalence/incidence study in a stable population. Neurology 1991; 41: 887– 92. 19 T Riise, C Wolfson, eds. Oslo international think-tank on multiple sclerosis epidemiology. Proceedings of the opening seminar, Centre for Advanced Studies, Oslo, Norway. Acta Neurol Scand 1995; 161: 1– 99. 20 T Riise, C Wolfson, eds. The epidemiologic study of exogenous factors in the etiology of multiple sclerosis. Neurology 1997; 49: S1– 82. 21 Dahl OP, Aarseth JH, Myhr KM, Nyland H, Midgard R. Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurol Scand 2004; 109: 378– 84. 22 Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005; 65: 1961– 3. 23 Grytten N, Glad SB, Aarseth JH, Nyland H, Midgard R, Myhr K-M. A 50-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Norway. Neurology 2006; 66: 182– 6. 24 Myhr K-M, Riise T, Green Lilleas FE et al. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 1999; 52: 1049– 56. 25 Myhr K-M, Riise T, Vedeler C et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001; 7: 59– 65. 26 Nortvedt MW, Riise T, Myhr K-M, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999; 53: 1098– 103. 27 Wergeland S, Beiske A, Nyland H et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 2005; 12: 171– 5. 28 Beiske AG, Pedersen ED, Czujko B, Myhr K-M. Pain and sensory complaints in multiple sclerosis. Eur J Neurol 2004; 11: 479– 82. 29 Figved N, Klevan G, Myhr K-M et al. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatr Scand 2005; 112: 463– 8. 30 Myhr K-M, Raknes G, Nyland H, Vedeler C. Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS. Neurology 1999; 52: 1771– 6. 31 Torkildsen O, Vedeler CA, Ulvestad E, Aarseth JH, Nyland HI, Myhr K-M. High dose methylprednisolone induces FcgammaRI on granulocytes in MS-patients. J Neuroimmunol 2005; 167: 138– 42. 32 Torkildsen O, Utsi E, Mellgren SI, Harbo HF, Vedeler CA, Myhr K-M. Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology 2005; 115: 416– 21. 33 Lunding J, Midgard R, Vedeler CA. Oligoclonal bands in cerebrospinal fluid: a comparative study of isoelectric focusing, agarose gel electrophoresis and IgG index. Acta Neurol Scand 2000; 102: 322– 5. 34 Lorentzen AR, Celius EG, Ekstrom PO et al. Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. J Neuroimmunol 2005; 166: 197– 201. 35 Sawcer S, Ban M, Maranian M et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005; 77: 454– 67. 36 Andersen O, Elovaara I, Farkkila M et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 706– 10. 37 Oturai AB, Ryder LP, Fredrikson S et al. Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Mult Scler 2004; 10: 5– 8. 38 Fernandes Filho JA, Vedeler CA, Myhr K-M, Nyland H, Pandey JP. TNF-alpha and -beta gene polymorphisms in multiple sclerosis: a highly significant role for determinants in the first intron of the TNF-beta gene. Autoimmunity 2002; 35: 377– 80. 39 Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Am J Neuroradiol 2005; 26: 572– 7. 40 Bo L, Geurts JJ, Ravid R, Barkhof F. Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis. Neuropathol Appl Neurobiol 2004; 30: 106– 17. 41 Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003; 9: 323– 31. 42 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278– 85. 43 Beiske A, Celius EG, Edland A et al. Utredning og behandling av multippel sklerose. Den Norske Lægeforening, Skriftserie for leger: Utdanning og kvalitetsutvikling, 2000. 44 Sellebjerg F, Barnes D, Filippini G et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005; 12: 939– 46. 45 Sorensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817– 27. 46 Celius EG, Vandvik B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur J Neurol 2001; 8: 463– 9. 47 Alstadhaug KB, Olavsen J, Salvesen R. Occurrence of multiple sclerosis in Nordland, 1970–1999. Tidsskr Nor Laegeforen 2005; 125: 431– 3. 48 Gronlie SA, Myrvoll E, Hansen G, Gronning M, Mellgren SI. Multiple sclerosis in North Norway, and first appearance in an indigenous population. J Neurol 2000; 247: 129– 33. Citing Literature Volume113, Issues183May 2006Pages 37-40 ReferencesRelatedInformation